Dr. Nina Niu Sanford
@NiuSanford
GI Radiation Oncologist | Boston, @Princeton, @harvardmed, now @UTSWNews in Dallas | buying in bulk | @AAAS IF/THEN | Tweets=own | FCOI: https://t.co/EjwMnJKbth
ID:1064888789200527361
https://utswmed.org/doctors/nina-sanford/ 20-11-2018 14:30:46
3,4K Tweets
6,4K Followers
1,9K Following
Follow People
#GISeries : Where are the #RadOnc & #IRad ? Here they areā¦
Importance of collaboration/MultiD in #gism w/Dr. Nina Niu Sanford Jeff Ryckman Harris Chengazi
Full š£ļø
- cancernetwork.com/treatment-algoā¦
- Oncbrothers.com/liverdirectedtā¦
- Also on āOncology Brothersā podcast
#OncTwitter #MedTwitter CancerNetworkĀ®
Nice editorial in JAMA Oncology today urging caution in pts w near CR after total neoadjuvant therapy in rectal cancer.
Reported rates of conversion from nCR to cCR vary widely from 39% to 100%!
Completely agree these patients should be counseled re: uncertainty of pursuing organā¦
Out today in EJC, with Alyson Haslam and Vinay Prasad MD MPH āļøš
We explored the reliability of quality of life (QoL) results when a lot of patients quit a trial.
authors.elsevier.com/sd/article/S09ā¦
1/6
š§µ
Great to be part of Common Sense Oncology, whose mission - to prioritize outcomes that matter to patients - encapsulates my goal as a radiation oncologist.
Met and reunited w some awesome folks these past few days.
(PS all oncology meetings should have live music & poutine).
Nice work Edward Christopher "Chris" Dee, MD & team!
In well-selected patients, ablative RT may improve outcomes in locally recurrent pancreas cancer.
Dutch ARCADE RCT assessing this strategy, & Hyun Kim also developing trial through NRG.
Edward Christopher "Chris" Dee, MD - we need you in GI rad onc!
Our Rad Onc Purple Beam Team, led by Dr. Todd Aguilera MD PhD and Minda Hill, came in third place for overall fundraising for the #PanCANPurpleStride PanCAN! Dr. Aguilera also placed second for individual fundraising!
Thank you to Neil Newman for giving a lecture at RadOncUH University Hospitals CWRU School of Medicine on the management of hepatocellular carcinoma.
Nice pre-ASCO ESOPEC discussion Krishan Jethwa & Daniel Catenacci, Daniel Catenacci you know our rad onc talking points well š
Let's wait to see results. Folks also thought for sure FOLFIRINOX would be winner in PREOPANC2, and OS curves turned out superimposable.